BASILEA PHARMA

Basilea now expects 2026 sales of 310 million Swiss francs, a significant increase versus earlier estimates. Sales of core products Cresemba and Zevtera are projected to rise to around 250 million Swiss francs, supported by expected milestone payments of about 65 million. Operating profit is estimated at roughly 115 million Swiss francs and the cumulative cash‑flow target for Cresemba and Zevtera has been raised to 650 million. A combined phase‑2/3 study for the Ceftibuten‑Ledaborbactam program is planned to start in mid‑2027; phase‑3 results for Fosmanogepix are expected in mid‑2028. » More on finanzen.net

Asahi Kasei Therapeutics has begun a multicenter phase II study in Japan to investigate the safety and pharmacokinetics of the antifungal Cresemba (isavuconazole) in children at increased risk of serious fungal infections. Cresemba is already approved in Japan for adults and, in the US, Canada, Europe and China, also for children; a pediatric approval in Japan is still pending. Worldwide Cresemba sales amounted to USD 782 million in April 2025–March 2026, a 27% increase from the prior year. » More on finanzen.net

Basilea reports H1 2026 revenue up 14% to 119 million CHF and operating profit up 32% to 31.6 million CHF; net profit was 27.9 million CHF and net cash doubled to 105 million CHF. Drivers were strong Cresemba sales and higher licensing and other income; Cresemba product sales are around $782 million (+27% over 12 months). The company raised its full-year forecast and now expects about 15% revenue growth and roughly 40% growth in operating profit for 2026. The stock rose about 8.7% in premarket trading to $58.9, near the 52-week high. » More on de.investing.com

Basilea Pharmaceutica reported a strong first half of 2026: sales rose 14% to CHF 119m, net profit climbed 77% to CHF 30m and operating profit increased about 32% to CHF 32m, driven by robust demand for Cresemba. Management significantly raised full‑year targets and now expects revenue growth of around 15% (instead of ~10%) and operating profit growth of about 40% (instead of ~20%). In addition, the Phase‑3 program for Fosmanogepix is proceeding as planned, supporting the near‑term commercial potential of the pipeline; the stock jumped sharply and approached its 52‑week high. » More on de.investing.com

Basilea has received a further $30 million from U.S. agency BARDA for the Phase III development of the antifungal Fosmanogepix, triggered by reaching a patient threshold. This raises BARDA funding for the two projects, Fosmanogepix and BAL2062, to a total of $123 million. Under the entire twelve-year agreement up to $268 million could be provided. » More on finanzen.net